Zekaver Odabasi

Zekaver Odabasi

Auto-generated profile, based on publicly available information

Zekaver Odabasi

Marmara University

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Medical Mycology
Verified
Journal Article
Open access
PDF file
ZOZekaver Odabasi
Zekaver Odabasi
VPVictor L. Paetznick
Victor L. Paetznick
JRJose R. Rodriguez
Jose R. Rodriguez
ECEnuo Chen
Enuo Chen
MMMichael R. McGinnis
Michael R. McGinnis
LOLuis Ostrosky-Zeichner
Luis Ostrosky-Zeichner
(1→3)-beta-d-glucan is a well known cell wall constituent of fungal isolates that can be detected by assays in vivo and in vitro. Previous studies have shown that different fungal isolates may show different levels of reactivity with an assay for beta glucan. In this study we evaluated the in vitro reactivity of 127 clinical fungal isolates belonging to 40 different genera, with the Glucatell™ assay. The majority of the fungal isolates released high levels of beta glucan. Beta glucan test reactivity appears to be species-specific and this may reflect the beta glucan content of the organism.

25 October 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
ZOZekaver Odabasi
Zekaver Odabasi
AMAli Mert
Ali Mert

1 November 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ZOZekaver Odabasi
Zekaver Odabasi
VPVictor Paetznick
Victor Paetznick
JRJohn H. Rex
John H. Rex
LOLuis Ostrosky-Zeichner
Luis Ostrosky-Zeichner
The effects of protein binding on the activities of caspofungin, anidulafungin, and micafungin were evaluated againstCandidaandAspergillusspecies. Adding human serum sharply increased the MICs of micafungin and anidulafungin and modestly affected the MIC of caspofungin. The increase in MICs does not appear consistent with the rate of protein binding for the three compounds.

1 January 2011 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
AKArzu Kahveci
Arzu Kahveci
EAEbru Asicioglu
Ebru Asicioglu
ETElif Tigen
Elif Tigen
EAElif Ari
Elif Ari
HAHakki Arikan
Hakki Arikan
COCetin Ozener
Cetin Ozener
An 87 -year-old female who was undergoing peritoneal dialysis presented with peritonitis caused by Alcaligenes faecalis and Pantoea agglomerans in consecutive years. With the following report we discuss the importance of these unusual microorganisms in peritoneal dialysis patients.

1 June 2020 in Critical Care Explorations
Verified
Journal Article
Open access
ZOZekaver Odabasi
Zekaver Odabasi
ICIsmail Cinel
Ismail Cinel
Taking into consideration the multisystemic clinical and autopsy findings in “severe” coronavirus disease 2019 patients, viral sepsis would be a more accurate term to describe the whole clinical picture. The most significant pathophysiological components of this picture are intense cytokine release, prolonged inflammation, immunosuppression with T cell exhaustion, and the development of organ dysfunctions. Currently, the optimal treatment for severe coronavirus disease 2019 is uncertain. Supportive treatment and immunomodulators have a critical place in the treatment of severe patients until effective antivirals are developed. Interleukin-6 antagonists, one of the immunomodulating agents, appears to be effective in the treatment of cytokine storm, but some patients continue to have severe lymphopenia and immunosuppression. We believe it can be useful as immunomodulator therapy in critical coronavirus disease 2019 patients because of the benefits of immune checkpoint inhibitors in cancer and sepsis patients.

1 July 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ZOZ. Odabasi
Z. Odabasi
AKA. Karaalp
A. Karaalp
HCH. Cermik
H. Cermik
JMJ. Mohr
J. Mohr
ETE. T. Tigen
E. T. Tigen
VKV. Korten
V. Korten
The reduction of amphotericin B (AmB)-induced renal tubular apoptosis and nephrotoxicity by N -acetylcysteine (NAC) in a murine model was evaluated. Four groups of rats were treated with AmB for 5 days, and each group concomitantly received two doses of 30, 60, or 120 mg of NAC/kg of body weight/day or sterile water for 5 days. Groups that received concomitant NAC at any dose had significantly decreased levels of apoptosis compared to that in animals receiving AmB only (48.8% versus 27.4, 23.6, or 23.5%, respectively; P < 0.001).